Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adoptive cellular therapy.
Sznol M, Urba WJ. Sznol M, et al. Cancer Chemother Biol Response Modif. 1992;13:191-204. Cancer Chemother Biol Response Modif. 1992. PMID: 1389910 Review. No abstract available.
Adoptive cellular therapy.
Sznol M, Urba WJ. Sznol M, et al. Cancer Chemother Biol Response Modif. 1991;12:213-30. Cancer Chemother Biol Response Modif. 1991. PMID: 1931444 Review. No abstract available.
Adoptive immunotherapy.
Sznol M, Urba WJ. Sznol M, et al. Cancer Chemother Biol Response Modif. 1994;15:213-25. Cancer Chemother Biol Response Modif. 1994. PMID: 7779587 Review. No abstract available.
Adoptive immunotherapy.
Sznol M, Urba WJ. Sznol M, et al. Cancer Chemother Biol Response Modif. 1993;14:227-48. Cancer Chemother Biol Response Modif. 1993. PMID: 8312104 Review. No abstract available.
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.
Curti BD, Ochoa AC, Urba WJ, Alvord WG, Kopp WC, Powers G, Hawk C, Creekmore SP, Gause BL, Janik JE, Holmlund JT, Kremers P, Fenton RG, Miller L, Sznol M, Smith JW 2nd, Sharfman WH, Longo DL. Curti BD, et al. Among authors: sznol m. J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):296-308. doi: 10.1097/00002371-199607000-00005. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8877723 Clinical Trial.
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M, Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, et al. Sznol M, et al. J Natl Cancer Inst. 1992 Jun 17;84(12):929-37. doi: 10.1093/jnci/84.12.929. J Natl Cancer Inst. 1992. PMID: 1629914
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW 2nd, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL. Fenton RG, et al. Among authors: sznol m. J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):364-74. doi: 10.1097/00002371-199609000-00006. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8941876 Clinical Trial.
246 results